Literature DB >> 6502404

Hypermetropia in accommodative esodeviation.

E L Raab.   

Abstract

Contradicting earlier doctrine, several studies have indicated that hypermetropia in childhood increases over the first seven years of life, and decreases thereafter. No clear consensus exists as to these characteristics in patients with accommodative esodeviation. In 68 subjects (136 eyes), the mean annual change in hypermetropia up to the seventh birthday was an increase of +0.19 +/- 0.36 D. Subjects whose accommodative deviation deteriorated showed changes similar in magnitude. The corresponding mean annual change in a previously reported age-matched series unselected for strabismus was +0.28 D. Hypermetropia in accommodative esodeviation showed a mean annual decrease between ages 7 and 13 years of -0.18 +/- 0.25 D. The corresponding finding in the general childhood population was -0.22 D. While clinically important individual departures from these results do occur, an accelerated rate of increase in hypermetropia is not characteristic of most cases of either controlled or of deteriorated accommodative esodeviation.

Entities:  

Mesh:

Year:  1984        PMID: 6502404

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  3 in total

1.  The influence of refractive error management on the natural history and treatment outcome of accommodative esotropia (an American Ophthalmological Society thesis).

Authors:  Bradley Charles Black
Journal:  Trans Am Ophthalmol Soc       Date:  2006

2.  Longitudinal Development of Refractive Error in Children With Accommodative Esotropia: Onset, Amblyopia, and Anisometropia.

Authors:  Jingyun Wang; Sarah E Morale; Xiaowei Ren; Eileen E Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04-01       Impact factor: 4.799

3.  Long-term development of refractive error in refractive, nonrefractive and partially accommodative esotropia.

Authors:  Paolo Esposito Veneruso; Dario Bruzzese; Adriano Magli
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.